Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists

@article{Tramm2018StandardizedAO,
  title={Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists},
  author={Trine Tramm and Tina Di Caterino and Anne Marie Bak Jylling and Giedrius Lelkaitis and Anne‐Vibeke L{\ae}nkholm and P{\'e}ter Rag{\'o} and Tomasz Piotr Tabor and Maj‐Lis M{\o}ller Talman and Emmanouela Vouza},
  journal={Acta Oncologica},
  year={2018},
  volume={57},
  pages={90 - 94}
}
Abstract Introduction: In breast cancer, there is a growing body of evidence that tumor-infiltrating lymphocytes (TILs) may have clinical utility and may be able to direct clinical decisions for subgroups of patients. Clinical utility is, however, not sufficient for warranting the implementation of a new biomarker in the routine practice, and evaluation of the analytical validity is needed, including testing the reproducibility of decentralized assessment of TILs. The aim of this study was to… 

Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer

Integration of immunohistochemistry and gene expression analysis is a valuable strategy to score TILs in breast tumors with increasing intra- and interrater variability with higher TIL numbers.

Tumor-Infiltrating Lymphocytes in Breast Cancer: Evaluating Interobserver Variability, Heterogeneity, and Fidelity of Scoring Core Biopsies

There was a slight improvement in the interobserver variability for TIL-str and slight decline in iTu-Ly when ER+/HER2- cases were excluded, and the agreement in TILs scoring between the raters is acceptable.

Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring

In conclusion, integration of immunohistochemistry and gene expression analysis is a valuable strategy to refine TIL scoring in breast tumors.

Inter‐observer agreement of tumor infiltrating lymphocytes in primary HER2‐positive breast cancer and correlation between tissue microarray and full tumor‐sections

There is acceptable inter‐observer agreement of TILs assessment on full‐section but not TMAs and discrepancy between full‐sections and TMAs, while TMA preparation must include consideration for representation of both entire tumor area and tumor‐microenvironment to correctly define prognostic and predictive values of potential immuno‐related biomarkers.

Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma

The ability of a TIL-quantifying machine learning algorithm to predict survival in primary melanoma and the association of % TIL with recurrence-free survival (RFS), overall survival (OS), and Cox proportional hazards modeling and concordance indices is evaluated.

Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer

The reproducibility of sTILs assessment using this scoring aid in cases from routine practice was evaluated and the potential of the tool to overcome variability in scoring was explored to explore.

Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study

Investigation of the degree of interobserver variability in an international study of high stromal tumor-infiltrating lymphocytes in triple-negative breast cancer found it necessary to determine the ‘ideal’ sTILs threshold, and attempt to fine-tune the patient selection for sTils-based de-escalation of NAC regimens.

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

While TILs do not have level of evidence IA, they should be used as a prognostic factor with caution and with other accepted prognostic variables, such as tumour size and lymph node status, to inform clinicians and patients on their treatment options.

References

SHOWING 1-10 OF 162 REFERENCES

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  • R. SalgadoC. Denkert S. Loi
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
Current data on the clinical validity and utility of TILs in BC are reviewed in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections.

Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group

Acceptable agreement in TIL enumeration was observed, suggesting that the proposed methodology can be used to facilitate the use of TILs as a biomarker in research and clinical trial settings.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

This large international standardization project shows that reproducible evaluation of TIL is feasible in breast cancer and opens the way for standardized reporting of tumor immunological parameters in clinical studies and diagnostic practice.

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

Levels of lymphocytic subpopulations may identify breast cancers more amenable to immunomodulation and indicate additional strategies to enhance immunity in patients with low to moderate levels of TILs.

Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions

TILs have potential clinical utility in breast cancer in a number of areas, including prediction of responders to immune checkpoint blockade, identification of primary HER2-positive and triple-negative patients who have excellent prognoses and may thus be appropriate for treatment de-escalation and potentially incorporation into a neoadjuvant endpoint.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Comprehensive recommendations on preanalytical and analytical assessment, and interpretation and scoring of Ki67 were formulated based on current evidence, geared toward achieving a harmonized methodology, create greater between-laboratory and between-study comparability, and allow earlier valid applications of this marker in clinical practice.

The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

Rich TILs were significantly associated with better survival outcome in early TN-BC and should be considered as a strong prognostic factor in this subtype and support integrating immunotherapy with conventional therapy in future BC research.

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

The presence of tumor-associated lymphocytes in breast cancer is a new independent predictor of response to anthracycline/taxane neoadjuvant chemotherapy and provides useful information for oncologists to identify a subgroup of patients with a high benefit from this type of chemotherapy.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  • S. AdamsR. Gray S. Badve
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
It is confirmed that stromal lymphocytic infiltration constitutes a robust prognostic factor in TNBCs and studies assessing outcomes and therapeutic efficacies should consider stratification for this parameter.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  • S. LoiS. Michiels C. Sotiriou
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
Higher levels of TILs present at diagnosis were significantly associated with decreased distant recurrence rates in primary TNBC, and an association between higher levels ofTILs and increased trastuzumab benefit in HER2+ disease is reported for the first time.
...